Development of selective cannabinoid treatments for neuroinflammation

Inflammation of the brain is a symptom of many different types of brain diseases such as Alzheimer’s disease, multiple sclerosis, depression, stroke, and traumatic brain injury. If left untreated, the inflammation can become a chronic problem that causes further damage to the brain. Different types of cannabinoids are a promising source of potential treatments to dampen inflammation in the central nervous system without the side effects that accompany other anti-inflammatory drugs. Panag Pharma Inc. is a Halifax based biotechnology company that specializes in the development of cannabinoid-based formulations to reduce inflammation and pain. This partnership between Panag Pharma Inc. and Dalhousie University will produce new information about cannabinoid drugs that will help to develop new treatments for brain inflammation.

Faculty Supervisor:

Eileen Denovan-Wright

Student:

Partner:

Panag Pharma Inc

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Dalhousie University

Program: